InfraVia Growth investi dans Orakl Oncology pour prédire la réponse aux traitements anticancéreux avant les essais cliniques
The Series A, co-led by Norrsken VC and Singular, follows a breakthrough: Orakl's AI predicted cancer clinical trial outcomes prospectively with 90% accuracy.
WeAreBlow12 novembre 2026








